Glioblastoma (GBM) is the most malignant tumor of the central nervous system. Current first-line post-surgery regimens for GBM including radiotherapy and temozolomide (TMZ) chemotherapy show very limited efficacy, with a median overall survival of only 15 months. Therefore, the development of therap...
ORGANISM(S): Homo Sapiens
